C.R.C. c/o Policlinico G. B. Rossi
P.le L. A. Scuro 10
37134 Verona - Italy
info@crc.vr.it

The CRC can provide fully eCTD/CDISC compliant Data Management and Statistics services integrated bioanalytical and pharmacokinetic services via strategic partners such as CROS NT -Accelera S.r.l. - Aptuit srl

A new collaboration with  Ablycon s.r.l. has been set up. Ablycon can help you tailoring the best scientific strategy to characterize the abuse liability properties of  the  molecules you are developing, so that you can confidently meet current regulatory requirements. A flexible case-to-case investigational approach will support your decision making process and your investments. Identification, in fact, of potential for abuse in a medicinal product involves its classification and scheduling, and seriously influences development, the prescribing practice and market access.

UNIQUE INTEGRATION OF CLINICAL KNOW-HOW AND TRIAL MANAGEMENT EXPERTISE

The CRC has been set up to develop new drugs in partnership with pharmaceutical industries or research organizations in the Respiratory, Gastrointestinal, Cardiovascular, Neurological, CNS, Diabetic, Urological, Ophthalmological and Oncological fields.

The CRC is owned by one of the top research-based General Hospitals in Italy and has access to leading Investigators in all Therapeutic Areas. The CRC is closely involved in defining and performing Proof-of-Concept studies using targeted populations, state-of-the-art human disease models and technology. In addition, a full range of Phase I services can be provided (e.g. drug-drug interaction, pharmacokinetics, food effects, bioequivalence) by means of an in-house Clinical Pharmacology Unit, equipped to a high standard and operating in close connection with specialist intensive care expertise in Cardiology, Anesthesiology, Internal Medicine, Surgery and Neurology.